Search Result

Isoforms Recommended:	IRAK4

Results for "

IRAK-4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IRAK (117) AAK1 (1) Apoptosis (24) Autophagy (5) Bacterial (1) c-Met/HGFR (3) CCR (1) CDK (2) CXCR (1) Cyclic GMP-AMP Synthase (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (2) Endogenous Metabolite (2) Enolase (1) Environmental Pollutants (1) Ephrin Receptor (1) ERK (1) FGFR (1) FLT3 (10) Glucocorticoid Receptor (4) IFNAR (5) Interleukin Related (15) Itk (1) JAK (2) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (9) MAP3K (2) MAP4K (2) MELK (1) MyD88 (9) NADH Dehydrogenase (1) NF-κB (18) NO Synthase (1) p38 MAPK (6) Pim (1) PROTAC Linkers (3) PROTACs (29) Reactive Oxygen Species (ROS) (2) Reference Standards (8) Small Interfering RNA (siRNA) (3) STAT (2) TGF-β Receptor (4) TNF Receptor (8) Toll-like Receptor (TLR) (9) Trk Receptor (1) ULK (1) Wee1 (1)
By Research Areas:	Cancer (77) Infection (7) Inflammation/Immunology (86) Metabolic Disease (2) Neurological Disease (6)
Click Chemistry:	PROTAC Synthesis (1)
Oligonucleotides:	CpG ODNs (4) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

150

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: IRAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145483

KT-474 1 Publications Verification KYM-001; PROTAC IRAK4 degrader-7	PROTACs IRAK Apoptosis	Cancer
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

HY-B1829A

Dexamethasone phosphate disodium 10+ Cited Publications Dexamethasone 21-phosphate disodium	Glucocorticoid Receptor TGF-β Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Dexamethasone phosphate (Dexamethasone 21-phosphate) disodium is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate disodium is produced by introducing a phosphate ester group at the 21-position of the Dexamethasone molecule, forming a salt with sodium ions, thereby significantly improving water solubility. Dexamethasone phosphate disodium inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate disodium inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate disodium is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate disodium can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease) ^[4] .

HY-18992

AS2444697	IRAK	Inflammation/Immunology
AS2444697 is an orally active *IRAK-4* inhibitor with an IC₅₀ of 21 nM . AS2444697 potently inhibits human and rat IRAK-4 activity. AS2444697 exhibits renoprotective effects through anti-inflammatory action .

HY-41547

Thalidomide 4-fluoride Cereblon ligand 4; E3 ligase Ligand 4	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966) .

HY-139374

Zabedosertib 2 Publications Verification BAY 1834845	IRAK	Inflammation/Immunology
Zabedosertib (BAY 1834845) is a selective, orally active *IRAK4* inhibitor with immunomodulatory potential, IC₅₀ is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .

HY-W087383

Thalidomide 5-fluoride	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 5-fluoride is a thalidomide-based Cereblon ligand used to recruit Cereblon protein. Thalidomide 5-fluoride can be linked to target protein ligands (e.g. *IRAK4) through a linker to form PROTAC molecules (e.g. PROTAC IRAK4* degrader-1). PROTAC IRAK4 degrader-1 caused <20%, >20-50%, and >50% IRAK4 protein degradation in OCI-LY-10 cells at concentrations of 0.01, 0.1, and 1 μM, respectively .

HY-111101

AZ1495	IRAK	Cancer
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 *(IRAK4)* inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC₅₀ values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a K_d value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-114181

IRAK4-IN-4 1 Publications Verification	IRAK Cyclic GMP-AMP Synthase	Inflammation/Immunology
IRAK4-IN-4 (Compound 15) is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, with an IC₅₀ of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC₅₀ of 2.1 nM. IRAK4-IN-4 can be used for research of autoimmune diseases .

HY-101922

IRAK4-IN-1	IRAK	Inflammation/Immunology
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-129966

*PROTAC IRAK4* degrader-1** 1 Publications Verification	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-1 (compound I-210) is a Cereblon-based IRAK4 PROTAC. PROTAC IRAK4 degrader-1 is composed of IRAK4 ligand (red part) PROTAC IRAK4 ligand-1 (HY-129967), E3 ligase ligand (blue part) Pomalidomide (HY-10984), and PROTAC linker (black part) AM-Imidazole-PA-Boc (HY-129968) .

HY-135382A

*PROTAC IRAK4* degrader-3**	PROTACs IRAK	Inflammation/Immunology
PROTAC IRAK4 degrader-3 is a PROTAC-induced *IRAK4* degrader based on von Hippel-Lindau .

HY-109585

IRAK4-IN-7	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .

HY-147264

Edecesertib GS-5718	IRAK	Inflammation/Immunology
Edecesertib (GS-5718) is a selective, potent, orally active *IRAK-4* inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research ^[4] .

HY-77048

IRAK-4 protein kinase inhibitor 2	IRAK	Inflammation/Immunology
IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC₅₀ of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders .

HY-13275

IRAK inhibitor 1	IRAK	Inflammation/Immunology
IRAK inhibitor 1 is a potent *IRAK-4* inhibitor with IC₅₀ of 216 nM, is poorly active against JNK-1 and JNK-2 with IC₅₀ of 3.801 μM, and >10 μM, respectively.

HY-148290

KTX-951	PROTACs IRAK	Cancer
KTX-951 is an orally active *IRAK4* and IMiD (Ikaros/Aiolos) substrates PROTAC degrader (K_d = 3.5 nM). KTX-951 has DC₅₀s of 13 nM, 14 nM and 13 nM for IRAK4, Ikaros and Aiolos, respectively. KTX-951 has IC₅₀ of 35 nM for OCl-Ly10 CTG. KTX-951 has antitumor activity.(Pink: IRAK4 ligand-12 (HY-48932); Black: Linker (HY-W382009); Blue: CRBN Ligand Pomalidomide (HY-10984)) .

HY-P5432

IRAK-4 Peptide substrate IRAK-1 (360-380)	IRAK	Others
IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. (This is a substrate peptide for Interleukin-1 Receptor-Associated Kinase (IRAK) 4)

HY-175764

FIP22	PROTACs IRAK NF-κB p38 MAPK TNF Receptor Interleukin Related	Inflammation/Immunology
FIP22 is a potent and selective IRAK4 PROTAC degrader (HEK293T cells: DC₅₀ = 3.2 nM; THP-1 cells: DC₅₀ = 10.6 nM). FIP22 induces the ubiquitin-proteasome system by forming an IRAK4-FIP22-CRBN ternary complex (EC₅₀ = 12.63 nM), thereby potently blocking IRAK4-mediated NF-κB and MAPK signaling pathways. FIP22 can be used for the study of atopic dermatitis (Pink: IRAK4 ligand (HY-175765); Blue: CRBN ligand (HY-W087383); Black: Linker (HY-46871)) .

HY-153224

GLPG2534	IRAK	Inflammation/Immunology
GLPG2534 is an orally active and selective *IRAK4* inhibitor, with IC₅₀ values of 6.4 nM and 3.5 nM for human and mouse IRAK4. GLPG2534 can be used for the research of inflammatory skin diseases .

HY-148238

GNE-2256	IRAK	Inflammation/Immunology
GNE-2256 (molecule 19), a chemical probe, is an orally active *IRAK4* (Interleukin 1 receptor associated kinase 4) inhibitor (IRAK4 *K_i*=1.4 nM; IL-6 IC₅₀=190 nM) .

HY-148274

KTX-582	PROTACs IRAK Apoptosis	Cancer
KTX-582 is a potent *IRAK4* degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88 ^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model .

HY-123854

PF-06426779	IRAK	Inflammation/Immunology
PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor associated kinase 4 (IRAK4), with an IC₅₀ of 0.3 nM .

HY-150735

IRAK4-IN-20	IRAK	Inflammation/Immunology
IRAK4-IN-20 (Compound BAY-1834845) is an orally active *IRAK4* inhibitor with an IC₅₀ of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .

HY-146112

IRAK4-IN-14	IRAK	Cancer
IRAK4-IN-14 (compound 28) is a potent, selective and orally active *IRAK4* inhibitor with an IC₅₀ of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib .

HY-151363

IRAK4-IN-21	IRAK	Inflammation/Immunology
IRAK4-IN-21 (compound 17) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 5 and 56 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-151365

IRAK4-IN-22	IRAK	Inflammation/Immunology
IRAK4-IN-22 (compound 18) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 3 and 17 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-129967

*PROTAC IRAK4* ligand-1**	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-153673

*PROTAC IRAK4* degrader-8**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC *IRAK4* degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively .

HY-175022

*PROTAC IRAK4* degrader-13**	PROTACs IRAK Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
PROTAC IRAK4 degrader-13 (Degrader 1) is a selective *IRAK4* PROTAC degrader with DC₅₀s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research . Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker

HY-145484

*PROTAC IRAK4* ligand-3**	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-3 is a ligand of PROTAC KT-474 (HY-145483) that can be used in cancer research .

HY-179094

PSP-0119	PROTACs IRAK NF-κB Enolase	Inflammation/Immunology Cancer
PSP-0119 is a highly efficient and effective PROTAC degrader targeting *IRAK4* (IC₅₀ = 2.83 nM). PSP-0119 can inhibit *IRAK4* kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML) .

HY-134911

HS-243	IRAK CDK	Inflammation/Immunology Cancer
HS-243 is a potent and selective *IRAK-4* and *IRAK-1* inhibitor, with IC₅₀ values of 20 and 24 nM. HS-243 shows minimal TAK1 (transforming growth factor β-activated kinase 1) inhibition activity, with a IC₅₀ of 0.5 μM. HS-243 shows anti-inflammatory and anticancer activity .

HY-159953

IRAK1/4/pan-FLT3 Kinase-IN-1	IRAK FLT3	Cancer
IRAK1/4/pan-FLT3 Kinase-IN-1 (Compound 31) is a potent inhibitor of *IRAK1, IRAK4, and FLT3* kinases, with an IC₅₀ of 5 nM for *IRAK1, 0.6 nM for IRAK4, and less than 0.5 nM for FLT3. IRAK*1/4/pan-FLT3 Kinase-IN-1 has good pharmacokinetic properties and shows promising potential for research in acute myeloid leukemia, with a survival prolongation effect comparable to that of Gilteritinib (HY-12432) .

HY-130253

IRAK4-IN-6	IRAK	Cancer
IRAK4-IN-6 is an orally efficacious and selective *IRAK4* inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma .

HY-135382

*PROTAC IRAK4* degrader-2**	PROTACs IRAK	Inflammation/Immunology Cancer
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC₅₀ in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC₅₀ of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .

HY-139316

*PROTAC IRAK4* degrader-5**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-5 is a Cereblon-based *IRAK4* degrader extracted from patent US20190192668A1, compound I-171 .

HY-177515

IRAK4 modulator-2	IRAK STAT JAK NF-κB	Inflammation/Immunology
IRAK4 modulator-2 (Compound 5) is a selective dual Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and *IRAK1* inhibitor with IC₅₀ values of 0.005 μM and 0.97 μM, erespectively. IRAK4 modulator-2 blocks IRAK-mediated signaling pathways (e.g., JAK-STAT, NF-κB pathways), reduces the production of pro-inflammatory cytokines (e.g., IL-1, TNF), and exerts anti-inflammatory activity. IRAK4 modulator-2 is promising for research of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease .

HY-139315

*PROTAC IRAK4* degrader-4**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .

HY-148276

KTX-497	PROTACs IRAK	Cancer
KTX-497 is an *IRAK4* PROTAC degrader with a DC₅₀ value of 3 nM. KTX-497 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-172590

LZ-07	PROTACs IRAK Interleukin Related TNF Receptor	Inflammation/Immunology
LZ-07 is a IRAK4 PROTAC degrader (DC₅₀ = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593) .

HY-B1829

Dexamethasone phosphate 10+ Cited Publications Dexamethasone 21-phosphate	Glucocorticoid Receptor TGF-β Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Dexamethasone phosphate (Dexamethasone 21-phosphate) is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate is prepared by introducing a phosphate ester group to the hydroxyl group at position 21 of the Dexamethasone molecule. Dexamethasone phosphate inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease) ^[4] .

HY-131903

HS271	IRAK	Inflammation/Immunology
HS271 is a highly potent, orally active and selective *IRAK4* inhibitor, with an IC₅₀ of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties .

HY-174470

IRAK4 ligand-14	Ligands for Target Protein for PROTAC IRAK	Inflammation/Immunology
IRAK4 ligand-14 is a ligand for IRAK4. IRAK4 ligand-14 can be used for synthesizing PROTACs such as APH02174 (HY-174455) .

HY-160654

IRAK4 modulator-1	IRAK	Inflammation/Immunology
IRAK4 modulator-1 (example 161) is a modulator of *IRAK4* with *IC₅₀*=4.647 μM. IRAK4 modulator-1 can be used to study IRAK-mediated disorders .

HY-168611

*PROTAC IRAK4* ligand-4**	Ligands for Target Protein for PROTAC IRAK	Cancer
PROTAC IRAK4 ligand-4 is a Ligand for Target Protein for PROTAC with antitumor activity. PROTAC IRAK4 ligand-4 can be used to synthesize PROTAC IRAK4 degrader-12 (HY-168586) .

HY-139317

*PROTAC IRAK4* degrader-6**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .

HY-E70731

IRAK4 aa104-460 Recombinant Human Active Protein Kinase	IRAK	Inflammation/Immunology
The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 aa104-460 Recombinant Human Active Protein Kinase is a recombinant IRAK4 aa104-460 protein that can be used to study IRAK4 aa104-460-related functions .

HY-13278

IRAK inhibitor 4 1 Publications Verification	IRAK	Inflammation/Immunology
IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

HY-13280

IRAK inhibitor 6	IRAK	Inflammation/Immunology
IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC₅₀ of 160 nM.

HY-155132

IRAK4-IN-28	IRAK	Inflammation/Immunology
IRAK4-IN-28 (compound 42) is an orally active *IRAK4* inhibitor (IC₅₀=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases .

Cat. No.	Product Name	Target	Research Area

HY-P5432

IRAK-4 Peptide substrate IRAK-1 (360-380)	IRAK	Others
IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. (This is a substrate peptide for Interleukin-1 Receptor-Associated Kinase (IRAK) 4)

Recombinant Proteins Recommended:

IRAK4

Species:	Human (4) Mouse (2)
Tag:	His (5) Tag Free (1) Strep (1)
Source:	sf9 insect cells (3) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703078

	IRAK4 Protein, Mouse (His) Interleukin-1 receptor-associated kinase 4; IRAK-4; EC:2.7.11.1	Mouse	E. coli
	IRAK4 Protein, Mouse (His) is the recombinant mouse-derived IRAK4, expressed by E. coli , with N-6*His labeled tag. ,

HY-P704729

	IRAK4 Protein, Mouse (Active, Sf9, His) Interleukin-1 receptor-associated kinase 4; IRAK-4; EC:2.7.11.1	Mouse	sf9 insect cells
	IRAK4 Protein, Mouse (Active, Sf9, His) is the recombinant mouse-derived IRAK4 protein, expressed by sf9 insect cells, with N-His tag.

HY-P73255

	IRAK4 Protein, Human (Active, sf9, His) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	Sf9 insect cells
	The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 Protein, Human (Active, sf9, His) is the recombinant human-derived IRAK4 protein, expressed by Sf9 insect cells , with N-10*His labeled tag.

HY-P705844

	IRAK4 Protein, Human (Active, sf9, His-Strep) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	sf9 insect cells

HY-P705845

	IRAK4 Protein, Human (Active, 307a.a, sf9) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	sf9 insect cells

HY-P702732

	IRAK4 Protein, Human (Active, 307a.a, sf9, His) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	Sf9 insect cells
	The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 Protein, Human (307a.a, sf9, His) is the recombinant human-derived IRAK4, expressed by Sf9 insect cells, with His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (2) Rabbit (3)
Reactivity:	Human (5) Rat (2) Mouse (3) Monkey (3)
Application:	IHC-P (5) ICC/IF (2) IHC-F (2) WB (5) FC (2) ELISA (2)
Isotype:	IgG (3) IgG1 (2)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85231

	IRAK-4 Antibody (YA4923)	WB, IHC-P	Human, Mouse, Monkey
	IRAK-4 Antibody (YA4923) is a Rabbit-derived and non-conjugated recombinant monoclonal antibody, targeting to IRAK-4.

HY-P84834

	IRAK4 Antibody (YA4531) IPD1; REN64; NY-REN-64	WB, IHC-P, FC, ELISA	Human, Mouse, Rat, Monkey
	IRAK4 Antibody (YA4531) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IRAK4.

HY-P83370

	IRAK4 Antibody (YA3115) IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; IPD1; IRAK4; LOC 51135; NY REN 64; REN64	WB, IHC-F, IHC-P, ICC/IF	Human
	IRAK4 Antibody (YA3115) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IRAK4.

HY-P83370A

	IRAK4 Antibody (YA3115)(PBS only) IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; IPD1; IRAK4; LOC 51135; NY REN 64; REN64	WB, IHC-F, IHC-P, ICC/IF	Human
	IRAK4 Antibody (YA3115) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IRAK4.

HY-P84834A

	IRAK4 Antibody (YA4531)(PBS only) IPD1; REN64; NY-REN-64	WB, IHC-P, FC, ELISA	Human, Mouse, Rat, Monkey
	IRAK4 Antibody (YA4531) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IRAK4.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-145483

KT-474 1 Publications Verification KYM-001; PROTAC IRAK4 degrader-7		PROTAC Synthesis
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

Cat. No.	Product Name		Classification

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909		CpG ODNs
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC₅₀ of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis ^[4] .

HY-150741

ODN 2216 1 Publications Verification		CpG ODNs
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150741C

ODN 2216 sodium 1 Publications Verification		CpG ODNs
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150750A

ODN M362 sodium		CpG ODNs
ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

HY-RS06899

Irak4 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Irak4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Irak4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06898

IRAK4 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
IRAK4 Human Pre-designed siRNA Set A contains three designed siRNAs for IRAK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS06900

Irak4 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Irak4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Irak4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: